Skip to main content
Premium Trial:

Request an Annual Quote

Argonaut Acquisition Would Boost Biotage s Annual Revenue by $17.6M

NEW YORK, May 4 (GenomeWeb News) - Biotage's impending acquisition of Argonaut Technologies, announced last month, would add around 125 million Swedish kronor ($17.6 million) to Biotage's annual top line, the company said today.


As GenomeWeb News reported, Biotage is "close" to closing a deal to acquire Argonaut for $21.2 million in cash.


The acquisition is expected to close "directly after" a shareholder's meeting in the second half of May, if Biotage shareholders vote in favor of the acquisition, Biotage CEO Jeff Bork said at the time.


However, Biotage today said that the acquisition must receive final approval by a special meeting of Argonaut shareholders, which will take place on June 1. Argonaut directors have already accepted Biotage's bid to acquire the business.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.